GATEWAY 2026
Threehorizons.
One company,
three doors.
Your bridge between the world and Japan's pharmaceutical & health industry.
7+
COUNTRIES
9+
PARTNERS
2023
FOUNDED
3
DOORS
Care Link
Specialty Pharma × Last Mile
Delivering directly to patients
Last-mile delivery of specialty pharmaceuticals from pharmacies to patient homes. End-to-end cold chain management, adherence monitoring, and PSP integration.
Global Bridge
Import × Export
A two-way bridge between Japan and the world
Japan market entry for overseas pharma and raw materials. Global expansion for Japanese OTC and supplements. Regulatory to logistics, end-to-end.
garden
Supplement Development
From idea to product
Supplement and health food planning to manufacturing. OEM/ODM, raw material sourcing, and branding support.
Latest Insights
Healthcare insights shared by CEO Masaya Yamamoto on NewsPicks
「分子のトロイの木馬」最終治験 ― 安全性・有効性・アクセスの三課題
The 'molecular Trojan horse' concept patented in 1989 has taken roughly 40 years to reach the final stage of clinical trials—a timeline that itself speaks to how difficult this approach truly is. The blood-brain barrier is a protective wall spanning the entire cerebral vasculature across some 640 kilometers, and the idea of exploiting receptor-mediated transport to ferry antibodies across it is technically impressive. Compared with conventional methods that required higher doses or intrathecal injection, delivering the drug in smaller amounts directly to the brain would be a meaningful advance. That said, what I most want to see is the safety profile. Existing amyloid antibody therapies have long struggled with ARIA—brain edema and microhemorrhages. Earlier-phase data suggest lower ARIA rates here, but because the antibody travels via receptor pathways, we need to watch for distinct adverse effects in non-brain tissues as well. On efficacy, the critical question is whether the degree of disease-progression slowing is large enough to be genuinely meaningful to patients and their families—something only the final results can confirm. In Japan, high-priced new drugs are also subject to cost-effectiveness-based price adjustments, so whether a scientific breakthrough actually translates into patient access will ultimately depend on how the post-approval regulatory framework is applied.
睡眠と認知症予防 ― 仮説から政策への飛躍を問う
Research into the brain's waste-clearance mechanisms is genuinely fascinating. The study cited in the article—collecting cerebrospinal fluid every hour for 36 hours—revealed a clear diurnal rhythm in amyloid-beta concentrations, peaking in the afternoon and falling overnight, lending real weight to the hypothesis that the brain cleans house during sleep. That said, I want to pause here. While sleep deprivation studies have shown that amyloid-beta levels rise under intervention conditions, the leap from that finding to 'improving sleep prevents dementia' remains enormous, and framing it simply as 'good sleep protects the brain' skips too many steps. There is also a population that tends to be overlooked: family caregivers whose sleep is chronically cut short by nighttime care duties. Before we turn sleep into a matter of individual effort, we need a policy conversation about how to protect caregivers' sleep structurally.
腸内細菌叢ビジネスの拡張 ― エビデンス段階の見極めが信頼を左右する
Applications of the gut microbiome are expanding well beyond digestion—into sports nutrition, healthy aging, weight management, and even the removal of PFAS and microplastics—and the sector is unmistakably becoming a broad-based industry, as illustrated by commercially launched strains like Synbio Tech's kimchi-derived TWK10. That said, the evidence underpinning the various claims sits at very different stages of maturity: findings from centenarian-derived strains remain at the mouse-study level, Akkermansia muciniphila's contribution to GLP-1 secretion is still described as 'suggestive,' and HMO-based improvements in elderly metabolic health are under 'investigation.' Because longevity and GLP-1 are among the most heavily funded buzzwords right now, preclinical results tend to migrate easily into product messaging. It is also worth remembering that the gut microbiome varies enormously between individuals, meaning the same strain will not necessarily work the same way for everyone. In Japan, functional labeling requires human-based evidence; the real test of trustworthiness in this field is whether sellers can clearly communicate which stage of evidence they are drawing on when overseas preclinical data flows into domestic product descriptions.